Physician profile
M Kholoki
NPI 1275679755
$4,273.47
in general payments reported to CMS, 2019-2025
29 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $355 · 2021: $1,638 · 2022: $612 · 2023: $499 · 2024: $189 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,278.89 | 2021 | |
| Abbvie INC. | $451.83 | 2021-2025 | |
| Novo Nordisk INC | $399.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $363.66 | 2019-2025 | |
| Lilly USA, LLC | $253.64 | 2020-2025 | Mounjaro, Kisunla, Zepbound |
| Janssen Pharmaceuticals, INC | $205.55 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $178.64 | 2021-2023 | Gvoke Hypopen, Keveyis |
| Astrazeneca Pharmaceuticals Lp | $172.65 | 2019-2022 | |
| Allergan, INC. | $144.24 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $100.81 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $89.61 | 2019-2025 | Eliquis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.12 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.70 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $65.38 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $49.94 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $47.75 | 2024-2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $40.71 | 2021 | |
| Amgen INC. | $39.39 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $38.16 | 2022 | |
| Horizon Therapeutics Plc | $31.13 | 2020 | |
| Astellas Pharma US INC | $25.95 | 2019-2021 | |
| Exact Sciences Corporation | $23.30 | 2025 | The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $20.56 | 2023 | Nuedexta |
| Strongbridge US INC. | $19.20 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.43 | 2023 | Xifaxan |
| Azurity Pharmaceuticals, INC. | $15.65 | 2023 | Edarbi |
| Glaxosmithkline, LLC. | $15.15 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.24 | 2022 | |
| Biogen, INC. | $14.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw M Kholoki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.